BEXBACT

This brand name is authorized in Nigeria.

Active ingredients

The drug BEXBACT contains a combination of these active pharmaceutical ingredients (APIs):

1	Betamethasone UNII 826Y60901U - BETAMETHASONE DIPROPIONATE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone
2	Neomycin UNII 057Y626693 - NEOMYCIN SULFATE
	Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.
	Read more about Neomycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100384	Cream	BEXBACT CREAM CREAM 0.05%; 1%; 0.5% 1X30GX10TUBES	BEXBACT CREAM CLOTRIMAZOLE USP 1%W/W, BETAMETHASONE DIPROPIONATE USP 0.05%W/W, NEOMYCIN SULFATE USP 0.5%W/W ACTIVE INGREDIENTS:CLOTRIMAZOLE USP 1%W/W, BETAMETHASONE DIPROPIONATE USP 0.05%W/W, NEOMYCIN SULFATE USP 0.5%W/W LIST OF EXCIPIENTS: (1) Chlorocresol (2) Petrolium Jelly (3) Cetostearyl Alcohol (4) C.M. -1000 (5) Light Liquid Paraffin (6) Propylene Glycol (7) Di.Sodium EDTA (8) Tween 80 (9) Purified Water Drugs Imported Products 1X30GX10TUBES Prescription Only Medicine (POM) 21/03/2023 TOP UGOLIFE PHARMACEUTICAL CO LTD, 13, JOSEPH ADEBAYOR STREET, AGO PALACE, OKOTA , LAGOS STATE. 8063125746 eugo37@yahoo.com ASTAMED HEALTHCARE (I) PVT LTD, Plot No. 2 & 3, Pase II, Genesis Ind. Complex, Kolgaon, Palghar - 401405, Maharashtra, India, India	26/04/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D07CC01	Betamethasone and antibiotics	D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07C Corticosteroids, combinations with antibiotics → D07CC Corticosteroids, potent, combinations with antibiotics
Discover more medicines within D07CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100384